Cite
MLA Citation
B. Han et al.. “134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study.” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172069101.0x000007